These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 3463543)

  • 1. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1986; 14 Suppl 3():S203-8. PubMed ID: 3463543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1985; 13(5):219-24. PubMed ID: 2933340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
    Well M; Naber KG; Kinzig-Schippers M; Sörgel F
    Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections].
    Naber KG; Adam D; Wittenberger R; Bartosik-Wich B
    Infection; 1986; 14 Suppl 1():S60-4. PubMed ID: 2420725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro selection of bacteria resistant to the 4-quinolone agents.
    Limb DI; Dabbs DJ; Spencer RC
    J Antimicrob Chemother; 1987 Jan; 19(1):65-71. PubMed ID: 3470281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative pharmacokinetics of five quinolones.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D; O'Hare MD; Robbins MJ; Wall RA; Williams AH; Cremer AW; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(5):317-29. PubMed ID: 2941259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H; Quentin C; de Barbeyrac B; Bebear C
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients.
    Naber KG; Adam D; Kees F
    Drugs; 1987; 34 Suppl 1():44-50. PubMed ID: 3481328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro activity of new quinolones against nonfermenters and references to sensitivity tests].
    Grimm H
    Infection; 1986; 14 Suppl 3():S191-5. PubMed ID: 3093387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Edlund C; Nord CE
    Scand J Infect Dis; 1986; 18(2):149-51. PubMed ID: 2939556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P
    Infection; 1986; 14(3):142-4. PubMed ID: 2942489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative in-vitro activity of ofloxacin.
    Grüneberg RN; Felmingham D; O'Hare MD; Robbins MJ; Perry K; Wall RA; Ridgway GL
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():9-19. PubMed ID: 3182468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
    Duncan IB; Skulnick M; Marshall PW
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():1-6. PubMed ID: 6438046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R; Griggs D; Andrews JM
    Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.